In some cases, the utility of patient genotyping prior to therapeutics is of unquestioned value.  In non-Hodgkin’s and Mantle Cell lymphoma, DNA sequencing of the tumor provides personalized cancer vaccines that demonstrate statistically significant Phase III clinical trial results with disease-free survival benefit in treatment of these types of follicular lymphoma [1]. The Oncotype DX® […]